Skin toxicity is among one of the most common AEs observed with ICPi and usually develops within the first few weeks after treatment initiation. However, serious skin toxicity is rare and usually does not require dose reductions, or treatment discontinuation. The most frequent skin AEs are rash, pruritus and vitiligo (typically in melanoma patients). More rarely, other skin AEs have been reported with checkpoint inhibitors: alopecia areata, stomatitis, pemphigus vulgaris, psoriasis and lichenoid skin reactions.
|Resolved to grade 0 or remain grade 1 with good tolerance||Worsened to grade > 2: see management guidelines for grade >2|
Click here for more detailed management guideline for grade 2 – 4 skin toxicity